what is known already: Storing ovarian tissue is an option to preserve fertility before gonadotoxic radiotherapy or chemotherapy treatments. However, transplantation of cryopreserved ovarian cortex to women cured of leukemia is currently not possible due to the risk of cancer re-seeding. study design, size, duration: We developed an automated ovarian cortex dissociation technique and we used eight-color FCM to identify leukemic cells with a series of dilutions added to ovarian single cell suspensions obtained from healthy cortex.
Introduction
Early detection and aggressive chemotherapy and/or radiotherapy treatments have considerably increased the long-term survival rates of young women with various types of cancer (Desandes et al., 2006; Howlader et al., 2012) . Unfortunately, these cytotoxic treatments generally result in the loss of both endocrine and reproductive functions, leading to premature ovarian failure and infertility (Donnez et al., 2006) . Loss of fertility has a major impact on the quality of life of young cancer survivors who, having overcome their disease, expect to have a normal reproductive life.
Progress in assisted reproductive technology has resulted in the availability of several options for preserving fertility in females prior to such potentially sterilizing treatments (Rodriguez-Wallberg and Oktay, 2012) . For women of childbearing age, fertility can be preserved by embryo or oocyte cryopreservation. However, as these techniques generally require ovarian stimulation, they are not suitable for women requiring immediate treatment and they may be contraindicated in cases of estrogen-sensitive tumors. Furthermore, embryo cryopreservation is not possible unless the woman has a male partner. For prepubertal patients and women who cannot delay the start of chemotherapy, cryopreservation of ovarian tissue is the main option available to preserve their fertility before cancer treatment (Salama et al., 2013) .
In the current absence of other techniques such as in vitro maturation or injection of isolated ovarian follicles (Smitz et al., 2010) , cryopreserved ovarian tissue can only be re-used by autograft and the prospect of restoring fertility by autotransplantation of frozen/thawed ovarian cortex is becoming increasingly real, with .20 live births already reported using this technique (Donnez et al., 2011a (Donnez et al., ,b, 2012 Revel et al., 2011; Dittrich et al., 2012) . However, autograft is only possible if the indication for ovarian cryopreservation is a non-neoplastic pathology (Roux et al., 2010) or a malignant pathology with a low risk of ovarian metastasis.
In cases of cancer with a high risk of ovarian metastatic localization, there is concern over the possible presence of malignant cells in ovarian cortical strips that could cause the primary disease to recur after reimplantation.
Hematological malignancies are the most frequent indications for ovarian tissue cryopreservation and represent almost 50% of all malignant indications. Of these, acute leukemia (AL) accounted for 11.3% or 38% according to the French GRECOT register (Groupe d'étude de la congélation d'ovaire et du testicule) in 2012. However, malignant cells may be present in the bloodstream running the risk of transferring diseased cells. Indeed AL is an aggressive neoplasia of hematopoietic progenitors involving bone marrow, blood and occasionally nodal or extranodal sites such as skin, the spleen or the central nervous system. Very little has been published on the safety of ovarian tissue transplantation in cases of cancer. An anatomopathological investigation of the autopsy material performed in Japan on 5571 autopsy findings of females aged under 40 has enabled us to estimate the likelihood of damage to the ovaries in cases of neoplastic pathology. In leukemia, the ovarian metastasis rate was 8.4% in the age bracket of patients who were likely candidates for ovarian tissue cryopreservation (Kyono et al., 2010) .
Apart from anatomopathological and/or immunohistological studies, only a few studies have conducted research on the detection of minimal residual disease (MRD) by molecular biology techniques in cryopreserved ovarian tissue. These studies investigated several pathologies: chronic myeloid leukemia (CML) (Meirow et al., 2008; Courbiere et al., 2010; Dolmans et al., 2010 ), Ewing's sarcoma (Abir et al., 2010) and AL Rosendahl et al., 2010; Greve et al., 2012; Rodriguez-Wallberg and Oktay, 2012) . However, these techniques are not yet sufficiently codified for use in clinical routine, particularly in cases of AL. Another method of evaluating the risk of re-developing cancer post-graft is by in vivo amplification of MRD by xenografting human ovarian tissue into an immunodepressed mouse (Kim et al., 2001; Dolmans et al., 2010; Greve et al., 2012) .
It therefore seems essential to make available techniques and markers that prove the absence of MRD in cryopreserved ovarian tissue. We will then be able to re-use ovarian tissue for reproductive purposes entirely safely using the autograft technique, especially for AL survivors (Rodriguez-Wallberg and Oktay, 2012) .
Two methods are used in hematology laboratories to access MRD quantification: PCR amplification of specific transcripts (for example BCR-ABL in CML) or IgH gene rearrangements using real-time clonespecific strategies (Gabert et al., 2003) and quantification of MRD by multicolor flow cytometry (FCM) (Campana, 2012) . In ovarian tissue, the FCM strategy allowed us to quantify neoplastic lymphoblasts specifically, by differentiating them from ovarian cells based on the identification of markers defining a leukemia-associated phenotype (LAP), which is expressed on leukemic lymphoblasts, but absent on normal hematopoietic cells and ovarian cells. However, because FCM had never been used previously in this setting, we needed to identify markers that clearly differentiate leukemic cells from ovarian cells.
Using a standardized protocol of tissue dissociation and FCM, we developed and validated a new technique to detect live leukemic cells in the ovarian cortex. We designed an experimental model of dilution of leukemic cells in cell populations isolated from the ovarian cortex, to evaluate the specificity and sensitivity of our method and the clinical feasibility of this approach. This is, to our knowledge, the first time such a model has been developed.
Materials and Methods

Collection of tissue and cells
Healthy ovarian tissue
The use of human ovarian tissue for this study was approved by the clinical ethics committee of Besançon University Hospital on 9 June 2010, and all patients gave their informed consent. Ovarian biopsies were obtained from women between 23 and 39 years of age (mean ¼ 29.94 years) undergoing laparoscopic ovarian drilling for polycystic ovary syndrome. Ovarian cortical fragments were obtained using biopsy grasping forceps from an avascular portion of the ovary devoid of visible follicles or luteal tissue, and before electrocoagulation of the puncture site. The specimens were immediately transported to the laboratory in Leibovitz L-15 medium (Sigma, SaintQuentin Fallavier, France) at 48C and they were used either immediately or after freezing-thawing.
Leukemic cells
Acute lymphoblastic leukemia (ALL) blood or bone marrow cells were collected at diagnosis frozen and stored at 21968C (n ¼ 10) (biological collection authorization no. DC-2008-713 , department of research and innovation; CRB F. Cabanne, Dijon-Besançon). Cells with the known LAP were used for leukemic cell dilution experiments in ovarian cell suspension.
Peripheral blood mononuclear cell
Peripheral blood mononuclear cells (PBMCs) from healthy donors were obtained after written informed consent (EFS Bourgogne Franche-Comté) and isolated on Ficoll-Hypaque (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) centrifugation.
Freezing and thawing procedure for ovarian tissue
Cortical biopsies were cryopreserved in cryovials containing freezing solution (1.5 mol/l dimethyl sulfoxide) (DMSO; Sigma, Saint-Quentin Fallavier, France) and 0.1 mol/l sucrose (Sigma) in Leibovitz L-15 medium supplemented with 10% decomplemented patient serum), according to a protocol using slow cooling with manual seeding (Gosden et al., 1994; Fauque et al., 2007) . After freezing, the vials were stored in liquid nitrogen.
Ovarian cortical biopsies were thawed according to the technique previously described (Roux et al., 2010) . The vials were air warmed for 30 s, then immersed in a 378C heat chamber (5 min), and the ovarian tissue pieces were washed in decreased solutions of DMSO 1.5 M (5 min), 1 M (5 min) and 0.5 M (10 min) and in a solution of 0.05 mol/l sucrose in Leibovitz L-15 medium supplemented with 10% decomplemented AB serum. The pieces were then rinsed in medium containing 20% serum only.
Isolation procedure for ovarian cells
A fragment of the ovarian cortex (weight: mean ¼ 96.8 + 68.3 mg; range ¼ 21 -276.4) was cut into small pieces of 1-2 mm 3 . These small pieces underwent mechanical and enzymatic dissociation by collagenase Ia (1.6 U/ml; Sigma) with DNase I (0.1 mg/ml; Roche Diagnosis, Meylan, France) in 5 ml of RPMI (PAA laboratories, Les Mureaux, France), using a cell dissociator (GentleMACSw; Miltenyi Biotec SAS, Paris, France) in combination with C Tubes (Miltenyi Biotec SAS). The use of this automated dissociator had to be optimized by adapting the program to ovarian tissue. This device is used for automated tissue dissociation in a closed and sterile system.
After filtration with a 70 mm cell strainer (Dutscher SAS, Brumath, France) and washing with 5 ml of RPMI, the cell suspension was centrifuged at 300g for 7 min at 48C and the pellet was resuspended with 1 ml of RPMI.
Morphological characterization of the isolated cells
Optical microscopy
Smears were made from isolated cells obtained from the ovarian cortex, fixed with alcohol ether and colored with Harris Shorr.
Electron microscopy
The cell suspension recovered from frozen/thawed tissue was centrifuged at 400g for 5 min. The pellet was fixed for 3 h at 48C in 2.5% glutaraldehyde (Sigma) in 0.1 M sodium cacodylate at pH 7.3, washed three times for 10 min in the same buffer, post-fixed in 1% osmium tetroxide (EMS; Euromedex, Souffelweyersheim, France) in 0.1 M sodium cacodylate at pH 7.3, washed three times for 10 min in the same buffer, treated in 0.1% tannic acid in cacodylate for 10 min, dehydrated in ascending series of ethanol and embedded in araldite (aralditew, accelerator and hardener, Fluka; Sigma Aldrich, Lyon, France). Ultrathin sections (60 nm) laid on nickel grids and stained with uranyl acetate and lead citrate were observed with a Philips CM10 electron microscope at 80 kV and images were taken on an Olympus SIS Morada camera.
Multicolor FCM detection of MRD
Eight-color FCM was performed using a BD CANTO II flow cytometer (BD Biosciences, San José, CA, USA) and data were analyzed using Diva 6 software (BD Biosciences, Le Pont de Claix, France). The compensation matrix was set up using compbeads& (BD Biosciences) according to the manufacturer's instructions. Daily quality control was performed using compbead setup and tracking beads& (BD Biosciences).
Antibodies
The same combinations of eight monoclonal antibodies (mAbs) were applied to ALL cells, to ovarian cell suspension and to different leukemic cell dilution experiments in ovarian cell suspension.
The antibody panel included fixed mAbs: 7-AAD (Beckman Coulter, Roissy, France) and SYTO13 (Invitrogen, Cergy Pontoise, France) to gate the live nucleated cells as described below and CD45 V500 (horizon 500, UCHT1; BD Biosciences) to characterize hematopoietic cells. The antibody panel also included variable mAbs expressed on leukemic cells at diagnosis (LAP) coupled: with phycoerythrin (PE), against the following antigens CD304 (AD5-17F6; Miltenyi Biotec, Paris, France) or CD58 (AICD58; Beckman Coulter) or CD13 (L138; BD Biosciences); with allophycocyanin, against CD10 (HI10a; Beckman Coulter) or CD123 (AC145; Miltenyi Biotec); with allophycocyanin H7 (APCH7), against CD3 (SK7; BD Biosciences) or CD38 (HB7; Beckman Coulter); with PE cyanin 7 (PC7), against CD19 (J3-119; Beckman Coulter) or cyCD3 (UCHT1; Beckman) or with V450, against CD3 (UTCH1; BD Biosciences) or CD7 (M-T701; BD Biosciences). Cytoplasmic antigen detection of CD3 (cyCD3) required a preliminary step of fixation and permeabilization (IntraStain, Dako).
Antibodies were added to 10 6 cells per tube in 50 ml of RPMI 1640 GlutaMax (Invitrogen, Cergy-Pontoise, France) and 10% fetal bovine serum (PAN Biotech GmbH, Aidenbach, Germany) and incubated for 20 min at 48C followed by washing with phosphate-buffered saline (PBS; Cambrex, Belgique). Cells were resuspended for acquisition in 100 ml of PBS. A defined number of calibrated 3-mm latex beads (Flowcount beads; Beckman Coulter) was added to each sample, as an internal standard in order to obtain the absolute value of different cells.
SYTO13 and 7-AAD can detect 7-AAD 2 and SYTO13 1 viable nucleated cells that are used to calculate the MRD level. Of the viable nucleated cells, CD45 1 leukocytes and T lymphocytes (CD3 + ) were identified. Variable markers (CD10, CD19, CD38, CD58, CD123 and CD304) were chosen to allow the identification of the B lymphoblastic population (CD19 + ) expressing an abnormal phenotype LAP. The major issue in the FCM strategy is to quantify neoplastic leukemic cells specifically by differentiating them from ovarian cells and normal lymphocytes coming from blood and possibly present in the ovarian cortex. These markers were chosen because they were expressed at a low level or not expressed at all by normal ovarian cells or mature lymphocytes.
Modelization of MRD assessment
For leukemic cell dilution experiments, the percentage and phenotype of leukemic cells were assessed after thawing by FCM. An initial dilution in ovarian cell suspension was made (dilution1) to obtain a suspension with a leukemic cell concentration of 10 -1 (10%). From this dilution, three or four suspensions were obtained by serial 1/10 dilutions (10 22 to 10 25 ). As previously described (Robillard et al., 2005; Solly et al., 2012) , total cells (1 × 10 6 /tube) were stained with the eight-color combination chosen for each ALL case. The acquisition was performed for a minimum of 0. 
RNA isolation and quantitative PCR analysis
Total RNA was isolated from the ovarian cell suspension containing increasing dilutions of leukemic cells, using RNeasy mini kit according to the Minimal residual disease in ovarian cortex manufacturer's instructions (Qiagen, France). cDNA was synthesized from total ovarian RNA using High Capacity RNA to cDNA MasterMixw kit (Applied Biosystems, France) at 428C for 30 min. Each cDNA sample (5 ml) was used for real-time (RT)-PCR amplification by using TaqMan polymerase from Applied Biosystems. In all cases, the quality of the cDNA products was assessed by monitoring human cRaf gene expression. Analysis of leukemia transcripts, BCR-ABL was performed by RT-quantitative (qPCR). For this purpose, each cDNA sample was added in triplicate to the PCR plate. The following program was used: enzyme activation cycle at 378C, 10 min; 508C, 2 min, a denaturation step at 958C for 15 min and 50 cycles of PCR (denaturation, 958C, 15 s; annealing, 628C, 1 min), then one cycle at 158C for 1 min. Negative controls (i.e. no template cDNA) were added to every experimental plate. The quantitative expression of mRNA was estimated using standard ABL and GAPDH as housekeeping genes.
Ovarian control patients
The ovarian tissue controls originated from deceased ALL patients who had undergone ovarian cryopreservation and had given their informed consent for the research. A T-ALL patient (positive control) had a cell invasion of abnormal lymphoblasts demonstrated at systematic histopathological examination performed at the time of ovary removal. Immunohistochemistry showed a positive CD3 membrane immunostaining of these infiltrating lymphoblasts within the ovarian tissue. The immunophenotype, performed on blood and bone marrow at the time of diagnosis, revealed CD2, CD7, CD13, CD10 and cyCD3 positive expression and absence of surface CD3 expression (sCD3), which is frequent in immature T-ALL. The following eight-color FCM tube was used for the analysis of this patient's ovarian tissue: 7-AAD/SYTO13/CD45/sCD3/cyCD3/CD7/CD10/CD13. All the available molecular markers were negative and no gene rearrangement was detected.
A B-ALL patient (negative control) had no ovarian invasion of abnormal lymphoblasts at histopathological examination. The immunophenotype, performed on blood and bone marrow at the time of diagnosis, revealed CD22, CD19, CD20 and CD10 expression. We performed the next FCM tube to analyze this patient's ovarian tissue using: 7-AAD/SYTO13/CD45/CD3/ CD19/CD20/CD22/CD10.
For each patient, the amount of tissue used for the FCM detection represented less than 8% of the total amount of cryopreserved tissue.
Statistical analysis
Data are expressed as the mean, coefficient of variation and/or standard deviation. The populations were compared using the student's t-test (P-values of 0.05 were considered to be significant). The comparison between the theoretical and experimental values of leukemic cell dilution modelization included regression analysis by the method of the least square.
Results
Isolation of ovarian cortex cells and quality assessment
The single-cell suspension obtained after ovarian cortex dissociation was analyzed by FCM according to its size (forward scatter, FSC) and granularity/nucleus -cytoplasm ratio (side scatter, SSC). In this population, we identified nucleated cells (SYTO13 1 ) and viable cells (7-AAD 2 ) to determine the percentage of viable nucleated isolated cells in each sample (Fig. 1A) , which was similar regardless of whether fresh ovarian cortex (46 + 18%; n ¼ 12) or frozen/thawed cortex (33 + 16%; n ¼ 20) was used (P ¼ 0.042).
The yield of the tissue dissociation technique, obtained for fresh or frozen ovarian tissue, was 1.83 + 1. We first had to ensure that the isolated cell suspension obtained from healthy ovarian cortex did not contain any cells coexpressing specific leukemic markers. Nucleated ALL cells showing a typical immunophenotype are displayed in Fig. 1B . Of the healthy ovarian viable nucleated cells, we selected CD45 and CD19 positive cells (i.e. B lymphocytes), and none of these non-contaminated ovarian cells had an LAP (Fig. 1C) .
Morphological controls performed on stained smears illustrated that this dissociation technique essentially produced single follicular and stromal cells, with only a few clusters of cells and dissociated collagen fibers observed after the isolation procedure (Fig. 2) . Transmission electron micrographs showed that cells isolated from both fresh and frozen/ thawed tissue had a well-preserved cytological architecture of the plasma membrane, the cytoplasmic organelles (membranous system and discrete particulate organelles) and the nuclear structures (Fig. 3) .
Sensitivity and specificity of the experimental model of minimal residual disease detection by eight-color FCM Before performing our experimental model for dilutions of leukemic cells in the ovarian cell suspension, we first checked that both isolated ovarian cells and added leukemic cells exhibit the same size and granularity profile allowing us to detect these cells by FCM in the same gate (Fig. 1B and C) . We then ensured that freezing -thawing and enzymatic dissociation protocols had no effect on the expression of cell surface markers used to identify leukemic cells (i.e. CD19, CD45 and CD10). We compared the mean fluorescence intensity (MFI) of these markers before and after the freezing/thawing/dissociation protocols on PBMCs (n ¼ 5), leukemic cells alone (n ¼ 5) or added to the ovarian cortex before isolation procedure (n ¼ 1) and we did not find any statistically difference in the MFI of each marker (data not shown). Therefore, the freezing/ thawing/dissociation steps did not modify cell surface marker expression on leukemic cells.
The modelization consisted in adding a decreasing number of ALL leukemic cells to the non-contaminated ovarian single-cell population. Ten different ALL cells were used (one per experiment of serial dilutions). All the different leukemic cells were well characterized by the expression of specific markers, defining their LAP and ensuring the specificity of their detection by FCM. Abnormal ALL cells were detected from the dilution of 10 21 to 10 25 (Fig. 4) . At the dilution of 10
25
, we detected fewer than the 20 abnormal events required (range 3-16), in relation to the insufficient number of total events analyzed. However, at the dilution of 10 24 , the number of abnormal events was equal to 48 + 13 (min ¼ 23), therefore conferring a sensitivity of 10 24 to this detection technique (Fig. 4) .
The comparison between theoretical and experimental values of leukemic cell quantification in the different dilutions showed a linear regression, with an excellent correlation between the theoretical and experimental cell numbers (r ¼ 0.9597, P , 0.001, n ¼ 45) (Fig. 5) .
When specific gene rearrangements (BCR-ABL) were present (n ¼ 5), the quantification of leukemic cells was performed both by FCM and RT-qPCR for each dilution (10 21 to 10
). For this purpose, the ovarian cell suspensions containing the different dilutions of leukemic cells were all divided into two equal parts.
If we consider a threshold of 10 24 leukemic cells to define MRD positively, no discordant results were observed between FCM and RT-qPCR and all detections attained the critical level of 10 24 with both assays. Furthermore, we observed a good correlation for abnormal leukemic cell quantification between RT-qPCR and FCM (r ¼ 0.8840, P , 0.0001, n ¼ 21) (Fig. 6) . At the dilution of 10 25 , RNA identification was negative by RT-qPCR in three cases out of five, while viable leukemic cells detected by FCM were under the 20 cell limit considered necessary for MRD positivity (3, 7 and 8 events, respectively). As evidence, an analysis of more total cells could allow us to obtain a sensitivity of less than Positive and negative control patients tested by FCM For the first patient (positive control), we detected 365 MRD positive events among 1.36 × 10 6 total alive nucleated events: MDR is therefore positive in the ovarian cortex at a level of 2.7 × 10 24 (Fig. 7A ).
For the second patient (negative control), no MRD positive event was detected within the ovarian cell suspension. The maximum sensitivity obtained in this MRD setting is 7 × 10 25 indicating that MRD is negative in the ovarian cortex for this patient at this maximum of sensitivity (Fig. 7B ).
Discussion
Although it has been successfully carried out in a rodent model, in vitro follicular culture technology and transplantation of frozen/thawed isolated primordial follicles are far from fully developed in humans (Carroll and Gosden, 1993; Picton et al., 2008) . Autograft is therefore currently the only available option to restore fertility by using cryopreserved ovarian cortex. However, ovarian cortex autograft has limitations, notably in cases of cancer, where the main concern of this procedure is the risk of reintroducing metastatic tumor cells with the implant. The risk of reintroducing a malignant condition when transplanting the tissue depends on the particular disease and a careful selection of patients for this procedure helps ensure that no relapse occurs after transplantation of ovarian cortex (Rosendahl et al., 2013) . Indeed, in cases of neoplastic pathology, the malignancy type and the activity of the disease are taken into account. Autografts are performed in patients with solid tumors (such as Hodgkin and non-Hodgkin lymphoma, sarcoma, breast cancer) presenting a low risk of ovarian localization. Only one case of successful autotransplantation of frozen/thawed ovarian tissue resulting in the birth of a healthy baby has been reported in a patient with metastatic disease (neuroectodermal tumor of the orbit), but no malignant cells were identified on serial sections of the frozen/thawed tissue (Donnez et al., 2011a,b) . representative of five independent experiments (axes in the log scale).
Minimal residual disease in ovarian cortex
When ovarian tissue is thawed, investigative studies to detect MRD must obviously be performed: they include conventional histological evaluation at macroscopic and microscopic levels and immunohistochemical staining (Meirow et al., 1998; Poirot et al., 2002; Seshadri et al., 2006; Meirow et al., 2008; Sanchez et al., 2009; Abir et al., 2010; Dolmans et al., 2010; Rosendahl et al., 2010 Rosendahl et al., , 2011 Bittinger et al., 2011; Greve et al., 2012) . If cancer cells are detected in ovarian tissue harvested for cryopreservation, the ovarian tissue cannot be reimplanted, as described by Bittinger et al. (2011) for Hodgkin lymphoma. However, the sensitivity of these techniques is limited (Bockstaele et al., 2012) .
AL is the most frequent type of malignancy in children and it usually requires highly gonadotoxic treatments. Cryopreservation of the ovarian cortex is often the only fertility preservation technique we can offer these patients, because we have little time for ovarian stimulation and because of the prepubertal age of these patients (Wallace et al., 2005; Donnez et al., 2006) . Immature oocyte retrieval in the luteal phase has been proposed to preserve fertility (Demirtas et al., 2008) , but so far no pregnancies have been reported with this technique in cancer patients.
As leukemia is a disease involving the bone marrow and the blood, malignant cells may be present in the blood-filled organs, including the ovaries. In cases of leukemia [ALL, acute myeloid leukemia (AML), chronic lymphoid leukemia, CML] or in the leukemic phase of lymphoma, malignant cells could be transferred during transplantation if leukemic cells are present in the ovarian cortex during freezing.
It has been reported that transplantation of testicular cells from leukemic donor rats transmits AL to healthy recipients. The number of leukemic cells sufficient to induce the disease in the rodent is, respectively, 20 and 200 cells by allograft and xenograft (Jahnukainen et al., 2001; Hou et al., 2007) .
Neither prior chemotherapy, nor preparing ovarian tissue in relation to cryopreservation, can completely eliminate ALL or CML cells Rosendahl et al., 2010) . On the other hand, these cytotoxic therapies may decrease the number of oocytes and they may be deleterious for oocyte quality, leading to a lower functional potential of the graft.
Until recently, residual leukemia or lymphoma in bone marrow, blood or lymph node cells was detected using different methods such as morphology, immunocytology, karyotype analysis or fluorescence in situ hybridization techniques or FCM using a single antibody. However, these techniques cannot detect small numbers of malignant cells. Molecular techniques (such as PCR) and FCM, seem to offer highly sensitive detection, with a high specificity from 10 24 up to 10 26 (Campana, 2012; Gaipa et al., 2012) . In the ovarian cortex, MRD detection for leukemia cannot be achieved using cytogenetic techniques, and histology and immunohistochemistry fail to locate leukemic cells in this tissue.
Rosendahl et al. analyzed cryopreserved ovarian cortex of 26 patients diagnosed with different types of leukemia (AML, ALL, CML, juvenile myelomonocytic leukemia): immunohistology did not reveal malignant cell infiltration in the ovarian cortex of any of the 26 patients. In 6 of the 8 patients (75%), disease-specific genetic markers (fusion transcript), originally found in the patients' bone marrow and blood during active disease, were detected in the ovarian cortex (Rosendahl et al., 2010) . Dolmans et al. evaluated the presence of leukemic cells in cryopreserved ovarian tissue from 18 leukemic patients: 12 with ALL and 6 with CML. If histology failed to identify malignant cells in the ovarian tissue, PCR analysis (detection of fusion gene transcripts or gene rearrangements) was positive for 7 of the 10 ALL with available molecular markers and for 2 of the 6 CML. Of these 7 ALL MRD positive patients, 3 had already received chemotherapy before ovarian tissue cryopreservation . In cases of leukemia, PCR positivity contraindicates ovarian autograft (Meirow et al., 2008; Courbiere et al., 2010; Dolmans et al., 2010; Rosendahl et al., 2010) .
Dolmans et al. also evaluated the presence of leukemic cells in cryopreserved ovarian tissue by achieving long-term (6 months) intraperitoneal xenografts in immunodeficient mice (SCID) (one mouse per patient). After grafting of ovarian tissue from the 12 ALL patients, 4 mice showed macroscopical intraperitoneal proliferation and another mouse presented a microscopic invasion. These five diseased mice had been transplanted with the ovarian cortex from ALL patients whose molecular markers were available and positive in four cases and unavailable in one case. However, the six mice grafted with ovarian tissue from CML patients remained healthy . Greve et al. recently complemented the study published by Rosendahl et al. (2010) by performing subcutaneous xenotransplantations of the ovarian cortex into nude mice for 20 weeks. The transplanted pieces originated from 25 patients with leukemia, with the majority of the patients in complete remission. No sign of disease was found in any of the mice according to macroscopic analysis, histological analysis and RT-qPCR, although the ovarian cortex showed a positive RT-qPCR result in four of the seven patients with a known molecular marker prior to transplantation (Greve et al., 2012) . Xenograft is currently the only available technique to assess the proliferative potential of malignant cells in the ovarian cortex. However, the technique has limitations. First, the xenograft should be kept for at least 6 months. Sixteen weeks seems to be too short a period for mice to develop disease when grafted with ovarian tissue from lymphoma patients (Kim et al., 2001) . Secondly, xenograft may not be a valid model for detecting MRD in cases of CML .
The technique we propose here uses an original and standardized protocol for dissociating fragments of the ovarian cortex. It involves population of isolated viable ovarian cells that can be analyzed by FCM, and by molecular technology depending on the availability of markers, to ensure MRD detection.
The use of an automated cell dissociator combining mechanical and enzymatic cycles and using a program previously adapted to ovarian tissue provide optimized conditions to obtain a satisfactory yield of live cells. On average, 100 mg of the dissociated ovarian cortex allowed us to obtain enough live cells to perform the entire FCM modelization procedure, itself containing five dilutions. We therefore used five times as much ovarian tissue than the amount required for MRD detection at 10 24 for one patient (20 positive events out of 200 000 total events).
Furthermore, when this cell dissociator is used in combination with C Tubes, tissue can be dissociated in a closed system, allowing for sterile sample handling. It was also useful for evaluating the results of the dissociation technique in terms of viability. For this purpose, trypan blue staining (Fauque et al., 2007) and a cell counting chamber are usually recommended. They could not be used here because of the presence of tissue and cell debris in cell suspensions, which interfered with the reading and the results themselves. We therefore used FCM and 7-AAD to identify viable cells, as this technique can detect a higher number of events than a microscopic count.
Leukemic cell dilution techniques in ovarian cells have enabled us to find abnormal leukemia cells from ALL up to a dilution of 10 24 (1 cell in 10 000 normal ovarian cells) conferring on the technique a robust sensitivity of 10
24
. FCM can detect one positive cell with certainty, but according to the literature, a cluster of at least 10 events with an LAP and back-gating light scatter is recommended to define a sample as 'MRD-positive' (Dworzak et al., 2008) . In our study, the minimum target sensitivity for qualifying MRD was defined as the ability to detect 20 MRD cluster events in 2 × 10 4 cellular events. This is because, unlike with PCR, the more positive events we detect with FCM the higher is the sensitivity. The sensitivity we obtained is similar to the standard threshold for MRD in blood and bone marrow in ALL (CoustanSmith et al., 2011) . The level of MRD threshold mandatory for ovarian tissue analysis should be specified in the future. In ovarian tissue, in which we search for the persistence of leukemic cells within non-hematopoietic cells, the FCM approach has the advantage of having many surface markers that can differentiate between ALL and ovarian cells. This approach can thus potentially be applied to 100% of AL patients, which is not the case for the molecular approach, especially when using transcript detection. Furthermore, the protocol we have developed allows for the absolute value quantification of leukemic cells using beads.
By analyzing viable cells, FCM may exclude dead leukemic cells, which could potentially yield false-positive results by PCR. Courbière et al. reported one case of CML, where RT-qPCR detected a low but positive level of BCR-ABL transcripts in blood and ovarian medulla, but the level was below the limit of quantification of the technique in the ovarian cortex (Courbiere et al., 2010) . Furthermore, there was no parallel in the transcript levels between the ovarian cortex and bone marrow or blood. Indeed, Dolmans et al. (2010) reported that the expression of the BCR-ABL fusion gene was higher in the ovarian cortex than in bone marrow in one patient with ALL and lower in two patients with CML. Rosendahl et al (2010) showed variable levels of molecular marker expression according to the fragments of ovarian tissue analyzed, which may partly be a result of insufficient fibrous ovarian tissue disruption and homogenization leading to a variability in RNA yield (Rosendahl et al., 2010) . In our modelization, RNA extractions were performed on isolated ovarian cell populations, which provided a homogeneous yield of RNA extraction and a level of RNA that was high enough to allow for cDNA amplification.
In conclusion, we used FCM with beads to quantify the presence of live leukemic cells from ALL in the ovarian cortex with a high specificity and sensitivity. This approach can be performed on fresh ovarian tissue during cryopreservation or on frozen/thawed tissue before reimplantation, and it i's currently the only available technique in cases of ALL where no molecular markers are identified.
The technique we propose here could also be transposed to testicular tissue from prepubertal cancer patients.
Making available MRD detection techniques (FCM, PCR and xenograft), which can be used either alone or together, is essential to add a fail-safe oncological dimension to pre-autograft monitoring. Controlling the cancer risk will, on the one hand, allow indications for cryopreservation of ovarian tissue to be broadened in young women presenting with a neoplastic pathology; on the other hand, it will encourage fragments of cryopreserved cortical ovarian tissue to be re-used by the autograft technique in patients at risk.
